机构：[1]Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin.Tianjin’s Clinical Research Center for Cancer, Tianjin, China[2]Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[3]Department for VIP, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[4]Head and Neck Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[5]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[6]Head and Neck Surgery, Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences.Cancer Hospital of the University of Chinese Academy of Sciences.Zhejiang Cancer Hospital.Zhejiang Provincial People’s Hospital.People’s Hospital of Hangzhou Medical College, Hangzhou, China浙江省肿瘤医院[7]Head and Neck Surgery Department, Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital), Nanjing, China[8]Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China[9]Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, China[10]Head and Neck Surgery Department I, Hunan Cancer Hospital, Changsha, China[11]Thyroid Surgery Ward, Harbin Medical University Cancer Hospital, Harbin, China[12]Department of Medical Oncology, Jilin Cancer Hospital, Changchun, Jilin, China[13]Department of Head & Neck Surgery, Tumor Hospital of China Medical University, Liaoning Tumor Hospital & Institute, Shenyang, China[14]Head and Neck Department, Fujian Cancer Hospital, Fuzhou, China[15]Thyroid & Head and Neck Surgery, Affiliated Cancer Hospital of Zhengzhou University. Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[16]Thyroid Surgery, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[17]Department of Thyroid Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院
第一作者机构：[1]Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin.Tianjin’s Clinical Research Center for Cancer, Tianjin, China
推荐引用方式(GB/T 7714)：
M. Gao,Y. Chi,P. Tang,et al.Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk[J].ANNALS OF ONCOLOGY.2020,31:S1088-S1088.doi:10.1016/j.annonc.2020.08.1408.
APA：
M. Gao,Y. Chi,P. Tang,X. Zheng,Z. Xu...&R. Cheng.(2020).Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk.ANNALS OF ONCOLOGY,31,
MLA：
M. Gao,et al."Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk".ANNALS OF ONCOLOGY 31.(2020):S1088-S1088
医学